Clinical Evidence

The TNBC subtypes have been reliably reproduced in every data set studied to date. These subtypes have also been shown to contain responder populations to various therapeutics (PARP, P13K, mTOR inhibitors, etc.)


2014 SABC

2015 ASCO

2016 SABC

Nagy GB, Santarpia L, Hatzis C. Molecular subtypes of triple negative breast cancer have different sensitivity to established chemotherapy agents. Poster P1-07-10. San Antonio Breast Cancer Symposium. 2017


Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN et al: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clinical Cancer Research: an official journal of the American Association for Cancer Research 2013, 19(19):5533-5540.

Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeijer T, Kluin RJ, Muris JJ, Jirström K, Kerkhoven RM, Wessels L, Caldas C, Bernards R, Simon IM, Linn S. BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Mol Oncol. 2015 Oct;9(8):1528-38.

Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, Viladot M5,6, Pineda E, Arance A, Muñoz M, Paré L, Cheang MC, Adamo B, Perou CM. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med. 2015 Dec 18; 13:303.

Wathieu H, Issa NT, Fernandez AI, Mohandoss M, Tiek DM, Franke JL, Byers SW, Riggins RB, Dakshanamurthy S. Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method. Oncotarget. 2017 Oct 9;8(54):92926-92942.

Lehmann BD, Bauer JA, Chen Xi, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767.

Barton VN, D’Amato NC, Gordon MA, et al. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015;14(3):769–778.

Lehmann BD, Jovanović, Bojana, Chen Xi, et al.  Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLOS. 2016.